Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
Portfolio Pulse from
Rani Therapeutics has announced preclinical data for RT-114, a GLP-1/GLP-2 dual agonist, demonstrating bioequivalence when delivered orally via their RaniPill® Capsule compared to subcutaneous administration. The study showed a relative bioavailability of 111%, successfully meeting the primary endpoint of bioequivalence.
March 26, 2025 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Preclinical data shows RaniPill® Capsule can effectively deliver GLP-1/GLP-2 dual agonist with comparable bioavailability to subcutaneous injection
Successful preclinical data demonstrates technological advancement in oral peptide drug delivery, which could significantly enhance the company's market potential and attract investor interest
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100